Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1994 1
1995 1
1996 1
1997 1
1999 1
2001 2
2011 1
2013 1
2014 2
2015 1
2016 1
2020 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Woolen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS. Woolen SA, et al. JAMA Intern Med. 2020 Feb 1;180(2):223-230. doi: 10.1001/jamainternmed.2019.5284. JAMA Intern Med. 2020. PMID: 31816007 Free PMC article.
Inclusion criteria consisted of stage 4 or 5 CKD with or without dialysis, administration of an unconfounded American College of Radiology classification group II GBCA (gadobenate dimeglumine, gadobutrol, gadoterate meglumine, or gadoteridol), and incident NSF as an outcom …
Inclusion criteria consisted of stage 4 or 5 CKD with or without dialysis, administration of an unconfounded American College of Radiology c …
Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast.
Petersein J, Saini S, Mitchell DG, Davis PL, Johnson CD, Kuhlman JE, Parisky YR, Runge VM, Weinreb J, Bernardino ME, et al. Petersein J, et al. AJR Am J Roentgenol. 1995 Nov;165(5):1157-61. doi: 10.2214/ajr.165.5.7572495. AJR Am J Roentgenol. 1995. PMID: 7572495 Clinical Trial.
T1-weighted spin-echo imaging and gradient-echo imaging were done before and within 1 min after (gradient echo) as well as 5 (spin echo) and 15 (spin echo) min after the injection of 0.1 or 0.3 mmol of gadoteridol per kg, randomized before the start of the study (39 patien …
T1-weighted spin-echo imaging and gradient-echo imaging were done before and within 1 min after (gradient echo) as well as 5 (spin echo) and …
Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
Katakami N, Inaba Y, Sugata S, Tsurusaki M, Itoh T, Machida T, Tanaka H, Nakayama T, Morikawa T, Breuer J, Aitoku Y. Katakami N, et al. Invest Radiol. 2011 Jul;46(7):411-8. doi: 10.1097/RLI.0b013e3182145a6c. Invest Radiol. 2011. PMID: 21467949 Clinical Trial.
The mean number of detected lesions per patient using the average of the 3 blinded readers was 6.28, 6.92, and 6.87 for gadobutrol 0.1 and 0.2 mmol/kg BW, and gadoteridol 0.2 mmol/kg BW, respectively. Noninferiority of gadobutrol (both doses) to gadoteridol 0.2 mmol …
The mean number of detected lesions per patient using the average of the 3 blinded readers was 6.28, 6.92, and 6.87 for gadobutrol 0.1 and 0 …
MR arthrography of the glenohumeral joint: two concentrations of gadoteridol versus Ringer solution as the intraarticular contrast material.
Binkert CA, Zanetti M, Gerber C, Hodler J. Binkert CA, et al. Radiology. 2001 Jul;220(1):219-24. doi: 10.1148/radiology.220.1.r01jn03219. Radiology. 2001. PMID: 11426001 Clinical Trial.
RESULTS: The mean CNR at imaging was 40.4 with 2 mmol/L gadoteridol, 45.6 with 4 mmol/L gadoteridol, and 48.7 with Ringer solution. The CNR with 2 mmol/L gadoteridol was significantly lower than that with 4 mmol/L gadoteridol (P =.025) and Ringer solut …
RESULTS: The mean CNR at imaging was 40.4 with 2 mmol/L gadoteridol, 45.6 with 4 mmol/L gadoteridol, and 48.7 with Ringer solu …
Efficacy of gadoteridol for magnetic resonance imaging of extracranial head and neck pathology.
Zoarski GH, Parker JR, Lufkin RB, Harnsberger HR, Rhoda CH. Zoarski GH, et al. Invest Radiol. 1992 Aug;27 Suppl 1:S53-7. Invest Radiol. 1992. PMID: 1506154 Clinical Trial.
RESULTS: Enhancement of pathology after gadoteridol injection was noted in 96 cases (78.7%) and provided additional diagnostic information in 57 cases (46.7%). ...CONCLUSION: These results demonstrate that gadoteridol is an efficacious agent for enhanced MRI of head …
RESULTS: Enhancement of pathology after gadoteridol injection was noted in 96 cases (78.7%) and provided additional diagnostic inform …
Efficacy of gadoteridol for magnetic resonance imaging of the brain and spine.
Runge VM, Bronen RA, Davis KR. Runge VM, et al. Invest Radiol. 1992 Aug;27 Suppl 1:S22-32. Invest Radiol. 1992. PMID: 1506150 Clinical Trial.
METHODS: Magnetic resonance imaging was performed before and after intravenous administration of 0.10 mmol/kg gadoteridol. Two groups of images were interpreted by one of two neuroradiologists blinded to patient history. ...CONCLUSIONS: Subjective assessment of magnetic re …
METHODS: Magnetic resonance imaging was performed before and after intravenous administration of 0.10 mmol/kg gadoteridol. Two groups …
Hepatic metastases and cavernous hemangiomas: distinction with standard- and triple-dose gadoteridol-enhanced MR imaging.
Mitchell DG, Saini S, Weinreb J, De Lange EE, Runge VM, Kuhlman JE, Parisky Y, Johnson CD, Brown JJ, Schnall M, et al. Mitchell DG, et al. Radiology. 1994 Oct;193(1):49-57. doi: 10.1148/radiology.193.1.8090921. Radiology. 1994. PMID: 8090921 Clinical Trial.
PURPOSE: To determine if hepatic metastases can be distinguished from cavernous hemangiomas by pattern analysis of magnetic resonance (MR) images obtained prior to and following administration of gadoteridol at standard (0.1 mmol/kg) and triple (0.3 mmol/kg) doses. MATERIA …
PURPOSE: To determine if hepatic metastases can be distinguished from cavernous hemangiomas by pattern analysis of magnetic resonance (MR) i …
Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study).
Maravilla KR, Smith MP, Vymazal J, Goyal M, Herman M, Baima JJ, Babbel R, Vaneckova M, Žižka J, Colosimo C, Urbańczyk-Zawadzka M, Mechl M, Bag AK, Bastianello S, Bueltmann E, Hirai T, Frattini T, Kirchin MA, Pirovano G. Maravilla KR, et al. AJNR Am J Neuroradiol. 2015 Jan;36(1):14-23. doi: 10.3174/ajnr.A4154. Epub 2014 Oct 9. AJNR Am J Neuroradiol. 2015. PMID: 25300984 Free PMC article. Clinical Trial.
BACKGROUND AND PURPOSE: Gadobutrol (Gadavist) and gadoteridol (ProHance) have similar macrocyclic molecular structures, but gadobutrol is formulated at a 2-fold higher (1 mol/L versus 0.5 mol/L) concentration. ...CONCLUSIONS: Gadoteridol and gadobutrol at 0.1 mmol/k …
BACKGROUND AND PURPOSE: Gadobutrol (Gadavist) and gadoteridol (ProHance) have similar macrocyclic molecular structures, but gadobutro …
Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded read.
Koenig M, Schulte-Altedorneburg G, Piontek M, Hentsch A, Spangenberg P, Schwenke C, Harders A, Heuser L. Koenig M, et al. Eur Radiol. 2013 Dec;23(12):3287-95. doi: 10.1007/s00330-013-2946-3. Epub 2013 Jul 4. Eur Radiol. 2013. PMID: 23824152 Clinical Trial.
OBJECTIVE: To prove that 1.0 M gadobutrol provides superior contrast enhancement and MRI image characteristics of primary and secondary brain tumours compared with 0.5 M gadoteridol, thereby providing superior diagnostic information. METHODS: Brain MRI was performed in two …
OBJECTIVE: To prove that 1.0 M gadobutrol provides superior contrast enhancement and MRI image characteristics of primary and secondary brai …
Phase III, randomized, double-blind, cross-over comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions.
Greco A, Parker JR, Ratcliffe CG, Kirchin MA, McNamara MT. Greco A, et al. Australas Radiol. 2001 Nov;45(4):457-63. doi: 10.1046/j.1440-1673.2001.00957.x. Australas Radiol. 2001. PMID: 11903179 Clinical Trial.
This study compares the efficacy and safety of gadoteridol with that of gadopentetate dimeglumine for enhanced MRI in subjects with intracranial lesions. A total of 92 subjects at three European centres underwent one MRI study enhanced with 0.1 mmol/kg gadoteridol a …
This study compares the efficacy and safety of gadoteridol with that of gadopentetate dimeglumine for enhanced MRI in subjects with i …
15 results